Summary & Overview
CPT 0620U: TruD MDS Hepatocellular Carcinoma Methylation Blood Test
CPT code 0620U designates a Proprietary Laboratory Analyses (PLA) test for TruD MDS Hepatocellular Carcinoma from TruDiagnostic™ Inc. This blood-based oncology molecular diagnostic analyzes DNA methylation at over 5,000 sites and uses an algorithm to categorize results as positive or negative risk for hepatocellular carcinoma. As a PLA code, 0620U applies to a single, manufacturer-specific laboratory test, which affects billing, coverage review, and comparisons across payers.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies and reimbursement approaches for PLA codes vary across national payers and between commercial plans and Medicare, making PLA codes like 0620U important for laboratory vendors, clinicians ordering the test, and revenue cycle stakeholders.
Readers will find: a concise clinical description of the test and service setting; an overview of payer coverage considerations for proprietary laboratory analyses; and guidance on the policy and coding context that typically surrounds single-manufacturer molecular diagnostics. Data not provided in the input (such as specific coverage policies, claim modifiers, or associated ICD-10 codes) are noted as unavailable.
Billing Code Overview
CPT code 0620U is a Proprietary Laboratory Analyses (PLA) code for the TruD MDS Hepatocellular Carcinoma test, produced by TruDiagnostic™ Inc. The assay analyzes DNA methylation at more than 5,000 sites using a whole blood sample and applies an algorithm to report a positive or negative risk for hepatocellular carcinoma.
Service type: Oncology molecular diagnostic test (proprietary laboratory analysis)
Typical site of service: Clinical laboratory or specialized diagnostic laboratory processing whole blood specimens
Data not available in the input for modifiers, taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with a history of chronic hepatitis C and cirrhosis is undergoing routine hepatocellular carcinoma (HCC) surveillance. The clinician orders a proprietary blood-based methylation assay, TruD MDS Hepatocellular Carcinoma (0620U) from TruDiagnostic™ Inc. A whole blood sample is collected in clinic and sent to the manufacturer’s lab. The laboratory performs DNA methylation analysis at >5,000 CpG sites and applies the test-specific algorithm to report a binary risk result (positive or negative). Results are returned to the ordering provider who incorporates the assay result with imaging (ultrasound, MRI), alpha-fetoprotein levels, and clinical assessment to guide next steps such as diagnostic imaging, specialist referral to hepatology or oncology, or closer surveillance intervals.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use if reporting only the physician interpretation component when the lab provides a separate technical component billing arrangement. |
TC | Technical component | Use when reporting only the laboratory technical component, if applicable under a split-billing arrangement.
59 | Distinct procedural service | Use when the lab test is reported on the same day as another unrelated lab or procedure and meets criteria for distinct service.